Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address sulli025@mc.duke.edu

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Overview
Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971

Publications

Feinstein, L. C., K. Seidel, J. Jocum, R. A. Bowden, C. Anasetti, H. J. Deeg, M. E. Flowers, et al. “Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts..” Biol Blood Marrow Transplant 5, no. 6 (1999): 369–78.

PMID
10595814
Scholars@Duke

Clift, R. A., C. D. Buckner, F. R. Appelbaum, K. M. Sullivan, R. Storb, and E. D. Thomas. “Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia..” Blood 92, no. 4 (August 15, 1998): 1455–56.

PMID
9694737
Scholars@Duke

Morton, A. J., T. Gooley, J. A. Hansen, F. R. Appelbaum, B. Bruemmer, J. W. Bjerke, R. Clift, et al. “Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase..” Blood 92, no. 2 (July 15, 1998): 394–401.

PMID
9657736
Scholars@Duke

Wagner, J. L., M. E. Flowers, G. Longton, R. Storb, M. Schubert, and K. M. Sullivan. “The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation..” Bone Marrow Transplant 22, no. 2 (July 1998): 139–46. https://doi.org/10.1038/sj.bmt.1701313.

PMID
9707021
Full Text

Storb, R., C. Yu, H. J. Deeg, G. Georges, H. P. Kiem, P. A. Mcsweeney, R. A. Nash, et al. “Current and future preparative regimens for bone marrow transplantation in thalassemia..” Ann N Y Acad Sci 850 (June 30, 1998): 276–87. https://doi.org/10.1111/j.1749-6632.1998.tb10484.x.

PMID
9668549
Full Text

Sullivan, K. M., C. Anasetti, M. Horowitz, P. A. Rowlings, E. W. Petersdorf, P. J. Martin, R. A. Clift, et al. “Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry..” Ann N Y Acad Sci 850 (June 30, 1998): 312–24. https://doi.org/10.1111/j.1749-6632.1998.tb10488.x.

PMID
9668553
Full Text

Deeg, H. J., K. Seidel, and K. M. Sullivan. “Body weight and outcome of hematopoietic stem cell transplantation..” Am J Med 104, no. 6 (June 1998): 607–8. https://doi.org/10.1016/s0002-9343(98)00217-4.

PMID
9674727
Full Text

Deeg, H. J., W. Leisenring, R. Storb, J. Nims, M. E. Flowers, R. P. Witherspoon, J. Sanders, and K. M. Sullivan. “Long-term outcome after marrow transplantation for severe aplastic anemia..” Blood 91, no. 10 (May 15, 1998): 3637–45.

PMID
9572999
Scholars@Duke

Hansen, J. A., T. A. Gooley, P. J. Martin, F. Appelbaum, T. R. Chauncey, R. A. Clift, E. W. Petersdorf, et al. “Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia..” N Engl J Med 338, no. 14 (April 2, 1998): 962–68. https://doi.org/10.1056/NEJM199804023381405.

PMID
9521984
Full Text

Lopez-Cubero, S. O., K. M. Sullivan, and G. B. McDonald. “Course of Crohn's disease after allogeneic marrow transplantation..” Gastroenterology 114, no. 3 (March 1998): 433–40. https://doi.org/10.1016/s0016-5085(98)70525-6.

PMID
9496932
Full Text

Pages